<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29244860</article-id><article-id pub-id-type="pmc">5731748</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0189485</article-id><article-id pub-id-type="publisher-id">PONE-D-17-33375</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Elements</subject><subj-group><subject>Lithium</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Metabolic Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Renal System</subject><subj-group><subject>Kidneys</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Renal System</subject><subj-group><subject>Kidneys</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Sugar</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Sugar</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Sugar</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Sugar</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Albumins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Experimental Organism Systems</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Experimental Organism Systems</subject><subj-group><subject>Animal Models</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Diabetic Endocrinology</subject><subj-group><subject>Insulin</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Hormones</subject><subj-group><subject>Insulin</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Lithium reduces blood glucose levels, but aggravates albuminuria in BTBR-<italic>ob/ob</italic> mice</article-title><alt-title alt-title-type="running-head">Lithium in diabetic nephropathy</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5841-6461</contrib-id><name><surname>de Groot</surname><given-names>Theun</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Damen</surname><given-names>Lars</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kosse</surname><given-names>Leanne</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Alsady</surname><given-names>Mohammad</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Doty</surname><given-names>Rosalinda</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Baumgarten</surname><given-names>Ruben</given-names></name><role content-type="http://credit.casrai.org/">Funding acquisition</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sheehan</surname><given-names>Susan</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>van der Vlag</surname><given-names>Johan</given-names></name><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Korstanje</surname><given-names>Ron</given-names></name><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Deen</surname><given-names>Peter M. T.</given-names></name><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>The Jackson Laboratory, Bar Harbor, Maine, United States of America</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Physiology, Radboud University Medical Center, Nijmegen, The Netherlands</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Vivium Care Group, Huizen, The Netherlands</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Long</surname><given-names>David</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>UCL Institute of Child Health, UNITED KINGDOM</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>peter.deen@radboudumc.nl</email></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>e0189485</elocation-id><history><date date-type="received"><day>13</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 de Groot et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>de Groot et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0189485.pdf"/><abstract><p>Glycogen synthase kinase 3 (GSK3) plays an important role in the development of diabetes mellitus and renal injury. GSK3 inhibition increases glucose uptake in insulin-insensitive muscle and adipose tissue, while it reduces albuminuria and glomerulosclerosis in acute kidney injury. The effect of chronic GSK3 inhibition in diabetic nephropathy is not known. We tested the effect of lithium, the only clinical GSK3 inhibitor, on the development of diabetes mellitus and kidney injury in a mouse model of diabetic nephropathy. Twelve-week old female BTBR-<italic>ob/ob</italic> mice were treated for 12 weeks with 0, 10 and 40 mmol LiCl/kg after which the development of diabetes and diabetic nephropathy were analysed. In comparison to BTBR-WT mice, <italic>ob/ob</italic> mice demonstrated elevated bodyweight, increased blood glucose/insulin levels, urinary albumin and immunoglobulin G levels, glomerulosclerosis, reduced nephrin abundance and a damaged proximal tubule brush border. The lithium-10 and -40 diets did not affect body weight and resulted in blood lithium levels of respectively &#x0003c;0.25 mM and 0.48 mM. The Li-40 diet fully rescued the elevated non-fasting blood glucose levels. Importantly, glomerular filtration rate was not affected by lithium, while urine albumin and immunoglobulin G content were further elevated. While lithium did not worsen the glomerulosclerosis, proximal tubule function seemed affected by lithium, as urinary NGAL levels were significantly increased. These results demonstrate that lithium attenuates non-fasting blood glucose levels in diabetic mice, but aggravates urinary albumin and immunoglobulin G content, possibly resulting from proximal tubule dysfunction.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004963</institution-id><institution>Seventh Framework Programme</institution></institution-wrap></funding-source><award-id>PIOF-GA-2012-332395</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5841-6461</contrib-id><name><surname>de Groot</surname><given-names>Theun</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Niels Stensen Fellowship</institution></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5841-6461</contrib-id><name><surname>de Groot</surname><given-names>Theun</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>Society of Experimental Laboratory Medicine</institution></funding-source><principal-award-recipient><name><surname>Deen</surname><given-names>Peter M. T.</given-names></name></principal-award-recipient></award-group><funding-statement>This project received support from a grant from the Society of Experimental Laboratory Medicine to PMTD and a Niels Stensen Fellowship (nielsstensenfellowship.nl/nl) and Marie Curie Fellowship PIOF-GA-2012-332395 (<ext-link ext-link-type="uri" xlink:href="http://ec.europa.eu/research/mariecurieactions/about_en">ec.europa.eu/research/mariecurieactions/about_en</ext-link>) to TG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="1"/><page-count count="17"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Diabetes mellitus (DM) often leads to diabetic nephropathy, a progressive decline in kidney function. Diabetic nephropathy starts with hypertrophy of renal proximal tubules and hyperfiltration.[<xref rid="pone.0189485.ref001" ref-type="bibr">1</xref>] Release of growth factors, cytokines and pro-inflammatory markers consequently leads to oxidative stress, manifesting as tubular atrophy and interstitial fibrosis.[<xref rid="pone.0189485.ref002" ref-type="bibr">2</xref>&#x02013;<xref rid="pone.0189485.ref004" ref-type="bibr">4</xref>] A silent phase follows, as the glomerular filtration rate (GFR) turns back to normal.[<xref rid="pone.0189485.ref005" ref-type="bibr">5</xref>] After this period, a progressive decline in GFR, and thus kidney function, develops.[<xref rid="pone.0189485.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0189485.ref007" ref-type="bibr">7</xref>] This decline in renal function is histopathologically characterized by a substantial thickened glomerular basement membrane (GBM), increased diffuse or nodular glomerulosclerosis, hyaline arteriosclerosis, tubulointerstitial fibrosis and tubulointerstitial atrophy.[<xref rid="pone.0189485.ref008" ref-type="bibr">8</xref>] Diabetic nephropathy is diagnosed via standard criteria for chronic kidney disease (CKD): a GFR below 60 mL/min/1.73m<sup>2</sup> and/or more than 30mg albumin/g creatinine in urine.<sup>[</sup><xref rid="pone.0189485.ref009" ref-type="bibr"><sup>9</sup></xref><sup>&#x02013;</sup><xref rid="pone.0189485.ref011" ref-type="bibr"><sup>11</sup></xref><sup>]</sup> The high impact of diabetes as a cause for kidney disease is illustrated by the fact that 25&#x02013;40% of all patients who have DM for 20&#x02013;25 years eventually develop CKD.[<xref rid="pone.0189485.ref012" ref-type="bibr">12</xref>] Due to the large incidence of DM, ~43% of all patients with end-stage renal disease is caused by DM and this is expected to increase, as the World Health Organization recently reported that the prevalence of diabetes quadrupled between 1980 and 2014.[<xref rid="pone.0189485.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0189485.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0189485.ref014" ref-type="bibr">14</xref>]</p><p>The serine/tyrosine kinase glycogen synthase kinase 3 (GSK3) has been shown to play a prominent role in cellular glucose uptake and storage. In healthy individuals, glucose uptake is stimulated by binding of insulin to its receptor, as this activates the insulin receptor substrate-1 (IRS-1), PI3-kinase and Akt, which subsequently enhances the plasma membrane abundance of glucose transporter type 4 (GLUT4) therewith increasing cellular glucose uptake.[<xref rid="pone.0189485.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0189485.ref016" ref-type="bibr">16</xref>] Glucose storage is also activated by Akt, as it stimulates glycogen synthase activity leading to intracellular glucose storage in the form of glycogen.[<xref rid="pone.0189485.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0189485.ref018" ref-type="bibr">18</xref>] As GSK3 inhibits both IRS-1 and glycogen synthase, it attenuates cellular glucose uptake and glycogen storage.[<xref rid="pone.0189485.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0189485.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0189485.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0189485.ref020" ref-type="bibr">20</xref>] As a consequence, it has been thought that GSK3 inhibition could be beneficial in DM. Indeed, GSK3 activity/abundance was elevated in various tissues of diabetic animals and patients[<xref rid="pone.0189485.ref021" ref-type="bibr">21</xref>&#x02013;<xref rid="pone.0189485.ref023" ref-type="bibr">23</xref>] and GSK3 inhibition or haplo-insufficiency reduced insulin resistance and blood glucose levels in diabetic mice.[<xref rid="pone.0189485.ref024" ref-type="bibr">24</xref>&#x02013;<xref rid="pone.0189485.ref026" ref-type="bibr">26</xref>]</p><p>Interestingly, recent studies indicated that moderate GSK3 inhibition is also beneficial in the prevention and treatment of acute kidney injury (AKI). Firstly, inhibition of GSK3&#x003b2; in murine models of cisplatin- and ischemia/reperfusion-induced AKI boosted cell proliferation and the repair machinery of renal tubular epithelia, which coincided with increased levels of cyclinD1, c-Myc and HIF-1&#x003b1;.[<xref rid="pone.0189485.ref027" ref-type="bibr">27</xref>, <xref rid="pone.0189485.ref028" ref-type="bibr">28</xref>] Secondly, GSK3 inhibition in LPS or Adriamycin-induced AKI decreased pro-inflammatory signalling and attenuated glomerular damage.[<xref rid="pone.0189485.ref029" ref-type="bibr">29</xref>] Lastly, GSK3 inhibitors decreased ROS-dependent apoptosis of renal epithelial cells in rodents with paraquat-induced AKI.[<xref rid="pone.0189485.ref030" ref-type="bibr">30</xref>] In agreement with these findings, mice overexpressing a GSK3 variant, mediating resistance to inhibition by Akt, demonstrated albuminuria and glomerulosclerosis.[<xref rid="pone.0189485.ref031" ref-type="bibr">31</xref>] Altogether, these data indicated that GSK3 inhibition attenuates proximal tubule and glomerular damage.</p><p>Considering the beneficial effects of GSK3 inhibition in DM and renal injury, we hypothesized that GSK3 inhibition may attenuate development of diabetic nephropathy. The only clinically available GSK3 inhibitor is lithium, which inhibits GSK3 in a direct and indirect manner, by respectively acting as a competitor for Mg<sup>2+</sup> binding,[<xref rid="pone.0189485.ref023" ref-type="bibr">23</xref>] which is required for substrate phosphorylation, and by promoting its phosphorylation of GSK3&#x003b1; and GSK3&#x003b2; at serine 21 or 9, respectively, resulting in their inactivation.<sup>[</sup><xref rid="pone.0189485.ref020" ref-type="bibr"><sup>20</sup></xref><sup>]</sup> In clinics, lithium is used to treat patients with bipolar disorder in order to prevent episodes of mania using a daily dose of 900&#x02013;1800 mg.[<xref rid="pone.0189485.ref027" ref-type="bibr">27</xref>, <xref rid="pone.0189485.ref032" ref-type="bibr">32</xref>] It has been shown that this lithium dose leads in some patients to the development of kidney damage.[<xref rid="pone.0189485.ref027" ref-type="bibr">27</xref>, <xref rid="pone.0189485.ref033" ref-type="bibr">33</xref>] Importantly, however, Hu et al demonstrated that a subclinical daily dose of 100 mg lithium already suffices to reduce non-fasting blood glucose levels in diabetic patients.[<xref rid="pone.0189485.ref034" ref-type="bibr">34</xref>]</p><p>Therefore, we here investigated the effect of subclinical lithium doses on the development of diabetic nephropathy. For this, we used BTBR-<italic>ob/ob</italic> mice, a widely-accepted DM type 2 (DM2) model, as, due to a homozygous <italic>ob/ob</italic> mutation inducing leptin deficiency, these mice consume excessive amount of food, and develop obesity and diabetes. Importantly, the BTBR-<italic>ob/ob</italic> mice develop signs of both early and advanced human diabetic nephropathy, as they exhibit albuminuria at an age of 4 weeks and morphological glomerular lesions at an age of 8 weeks.[<xref rid="pone.0189485.ref011" ref-type="bibr">11</xref>]</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Animal model</title><p>Twelve-week old female wild-type and <italic>ob/ob</italic> BTBR <italic>T</italic><sup><italic>+</italic></sup>
<italic>Itpr3</italic><sup><italic>tf</italic></sup>/J (BTBR) mice were obtained from The Jackson Laboratory. Mice were housed at The Jackson Laboratory in a temperature-controlled room with a 12:12h light-dark cycle and had <italic>ad libitum</italic> access to water and food (standard chow (7013, NIH-31 Modified) or standard chow supplemented with respectively 10 and 40 mmol lithiumchloride (LiCl)/kg chow, Harlan Laboratories Inc, Madison, WI, USA). Immediately before sacrifice by cervical dislocation, which took place a few hours after initiation of the light cycle, blood was collected via submandibular bleeding. Kidneys were collected and processed for histology or immunoblotting, as described.[<xref rid="pone.0189485.ref035" ref-type="bibr">35</xref>] Animal studies were approved by The Jackson Laboratory's Institutional Animal Care and Use Committee.</p></sec><sec id="sec004"><title>GFR determination</title><p>GFR was determined using the FITC-Inulin clearance method.[<xref rid="pone.0189485.ref036" ref-type="bibr">36</xref>] At week 11, mice received a single bolus injection of dialysed FITC-inulin. Before FITC-inulin injection, blood was collected to determine baseline fluorescence. At 3, 5, 7, 10, 15, 35, 56, and 75 minutes after injection, blood was collected via the tail. Blood fluorescence was determined using a Cytofluor II Fluorescence Multiwell Plate Reader (PerSeptive Biosystems) with 485nm excitation and 538nm emission. Renal excretion rate of inulin was determined based on the decay fluorescence counts over time. Based on this excretion rate, the GFR was determined.</p></sec><sec id="sec005"><title>Glucose tolerance test</title><p>At 10 weeks, a glucose tolerance test was performed. After a 4-hour fast, mice received an intraperitoneal injection of 2 mg/g body weight glucose. Before and at 15, 30, 60 and 120 minutes after injection, blood was collected from the tail and glucose levels were immediately determined with a blood glucose meter (OneTouch Ultra<sup>&#x000ae;</sup>2). Before sacrifice, blood was collected by submandibular bleeding and non-fasting glucose levels were immediately determined using the blood glucose meter.</p></sec><sec id="sec006"><title>Blood and urine analysis</title><p>Blood was centrifuged at 3000xg for 5 minutes to separate serum from blood cells. Serum concentration of lithium was measured using The Medimate Mini-Lab (Enschede, The Netherlands). Insulin concentration in serum was measured using Ultra Sensitive Insulin ELISA (Cristal Chemical Inc.). Additional serum analyses of blood urea nitrogen (BUN) and neutrophil gelatinase associated lipocalin-2 (NGAL) were performed using the NCal NIST-Calibrated Kit (ARBOR ASSAYS) and Mouse-NGAL DuoSet Kit (RnD Systems) respectively. Urine was analysed for creatinine and albumin on a Beckman Synchron CX5 Chemistry Analyzer (Fullerton, CA, USA) by the Histology department of The Jackson Laboratory, as described[<xref rid="pone.0189485.ref037" ref-type="bibr">37</xref>], while urinary IgG levels were determined with the Mouse-IgG ELISA (Roche, V.10), and NAG-activity with NAG Activity Assay Kit (Abcam).</p></sec><sec id="sec007"><title>Histology</title><p>Kidney were isolated and stored in 3.5% PFA solution. After fixation for two days, kidneys were embedded in paraffin. Kidney slides were stained with Periodic acid-Schiff or Picro Sirius Red. Assessment of the slides was performed using blind randomization.</p></sec><sec id="sec008"><title>Immunoblotting</title><p>Immunoblotting was performed as described[<xref rid="pone.0189485.ref038" ref-type="bibr">38</xref>]. Primary antibodies included rabbit anti-cubilin and sheep anti-megalin (gifts from Prof. Pierre Verroust, INSERM, Paris, France), mouse anti-GSK3&#x003b2; (#610201, BD Biosciences), rabbit anti-pGSK3&#x003b2; (#9336S, Cell Signalling Technology) and guinea pig anti-nephrin (#20R-NP002, Fitzgerald Industries International). Proteins were visualized using enhanced chemiluminescence (Pierce) and the &#x0201c;ChemiDoc XRS&#x0201d; (Bio-Rad). For semi-quantification the QuantityOne software (Bio-Rad) was used, while Coomassie blue staining was used to determine and correct for total protein input.</p></sec><sec id="sec009"><title>RNA isolation, primer design and reverse transcription-quantitative PCR (RT-qPCR)</title><p>RNA from renal cortex was isolated using TRIzol&#x000ae; (Gibco Life Technologies, Rockville, MD, USA) and 1.5 &#x003bc;g of RNA was reverse transcribed using the Moloney murine leukemia virus reverse transcriptase kit (Promega, Madison, WI, USA), according to the suppliers&#x02019; protocol. Following a 10-fold dilution, mRNA levels were assessed by RT-qPCR using SYBR-green (Applied Biosystems, Foster City, CA, USA) and normalized to housekeeping gene <italic>Rplp0</italic> (36B4). Primer sequences were as listed in <xref ref-type="supplementary-material" rid="pone.0189485.s006">S1 Table</xref>.</p></sec><sec id="sec010"><title>Statistical analysis</title><p>All statistical analyses were performed in GraphPad Prism. Statistical analyses were performed using one-way ANOVA with Bonferroni correction. Differences were considered significant at p&#x0003c;0.05. Data are presented as means and SEMs.</p></sec></sec><sec sec-type="results" id="sec011"><title>Results</title><sec id="sec012"><title>GSK3 activity is increased in kidneys of ob/ob mice</title><p>Diabetic animals and patients demonstrated an increased abundance or decreased phosphorylation of GSK, indicative of an increased activity.[<xref rid="pone.0189485.ref021" ref-type="bibr">21</xref>&#x02013;<xref rid="pone.0189485.ref023" ref-type="bibr">23</xref>] As overexpression of active GSK3 caused albuminuria and glomerulosclerosis,[<xref rid="pone.0189485.ref031" ref-type="bibr">31</xref>] we first wanted to establish whether GSK3 activity was altered in 24-week old BTBR-<italic>ob/ob</italic> mice, as at this age these mice demonstrate diabetes, albuminuria and glomerular damage.[<xref rid="pone.0189485.ref011" ref-type="bibr">11</xref>] Using whole kidney homogenates of 24 week-old BTBR-wild type (WT) and BTBR-<italic>ob/ob</italic> mice, total and phosphorylated GSK3 abundance was examined by immunoblotting (<xref ref-type="fig" rid="pone.0189485.g001">Fig 1A and 1B</xref>). Semi-quantification demonstrated that total GSK3 abundance was not different between both groups, but that the pGSK3/GSK3 ratio was significantly decreased in BTBR-<italic>ob/ob</italic> mice, suggesting that diabetes caused GSK3 overactivity in the kidneys of these mice (<xref ref-type="fig" rid="pone.0189485.g001">Fig 1C</xref>).</p><fig id="pone.0189485.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0189485.g001</object-id><label>Fig 1</label><caption><title>pGSK3/GSK3 ratio in BTBR-WT and <italic>ob/ob</italic> mice.</title><p>Kidneys from 24-week old female BTBR-WT and -<italic>ob/ob</italic> mice were isolated and protein lysates were immunoblotted for pGSK3 and GSK3. Representative immunoblots for WT and <italic>ob/ob</italic> mice for (A) GSK3 and (B) pGSK3 are depicted. Corresponding densitometric analysis of (C) total GSK3 abundance and (D) pGSK3/GSK3 ratio (n = 9 per group). **p&#x0003c;0.01. Cm, Coomassie.</p></caption><graphic xlink:href="pone.0189485.g001"/></fig></sec><sec id="sec013"><title>Lithium reduces non-fasting blood glucose levels in ob/ob mice</title><p>To determine whether the GSK3 inhibitor lithium might constitute a treatment for diabetic nephropathy, we wanted to test the effect of lithium at a point in which early signs of diabetic nephropathy were already observed. In line with data from others,[<xref rid="pone.0189485.ref011" ref-type="bibr">11</xref>] our 12 weeks old BTBR-<italic>ob/ob</italic> mice demonstrated an increased body weight (53.6 vs 28.1 g, p&#x0003c;0.05) and elevated albumin creatinine ratio (ACR) as compared to WT mice (101.8 vs 12.0 mg/g, p&#x0003c;0.05). After randomizing for body weight and ACR, the <italic>ob/ob</italic> BTBR mice received standard chow (control) or chow supplemented with 10 (Li-10) or 40 (Li-40) mmol LiCl per kg food for 12 weeks (<xref ref-type="table" rid="pone.0189485.t001">Table 1</xref>). As a control for obesity/DM2 development in <italic>ob/ob</italic> BTBR mice, an additional group of WT mice only received standard chow. The Li-10 and -40 diets did not affect body weight and led to serum lithium levels of &#x0003c;0.25 mM and 0.48 &#x000b1; 0.04 mM, respectively (<xref ref-type="table" rid="pone.0189485.t001">Table 1</xref>). These levels are subclinical as in bipolar patients a range of 0.6&#x02013;1.0 mM is maintained.</p><table-wrap id="pone.0189485.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0189485.t001</object-id><label>Table 1</label><caption><title>Body weight and lithium levels.</title></caption><alternatives><graphic id="pone.0189485.t001g" xlink:href="pone.0189485.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" style="border-top:thick" rowspan="1" colspan="1">Group</th><th align="justify" colspan="3" style="border-top:thick" rowspan="1">Bodyweight (g)</th><th align="justify" style="border-top:thick" rowspan="1" colspan="1">Lithium (mM)</th></tr><tr><th align="justify" rowspan="1" colspan="1"/><th align="justify" rowspan="1" colspan="1">Week 0</th><th align="justify" rowspan="1" colspan="1">Week 6</th><th align="justify" rowspan="1" colspan="1">Week 12</th><th align="justify" rowspan="1" colspan="1">Week 12</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1"><bold>WT</bold></td><td align="justify" rowspan="1" colspan="1">28.1 &#x000b1; 0.6</td><td align="justify" rowspan="1" colspan="1">32.3 &#x000b1; 0.9</td><td align="justify" rowspan="1" colspan="1">35.5 &#x000b1; 1.3</td><td align="justify" rowspan="1" colspan="1">ND</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold><italic>ob/ob</italic></bold></td><td align="justify" rowspan="1" colspan="1">53.6 &#x000b1; 1.3<xref ref-type="table-fn" rid="t001fn002">***</xref></td><td align="justify" rowspan="1" colspan="1">73.4 &#x000b1; 1.3<xref ref-type="table-fn" rid="t001fn002">***</xref></td><td align="justify" rowspan="1" colspan="1">83.5 &#x000b1; 2.4<xref ref-type="table-fn" rid="t001fn002">***</xref></td><td align="justify" rowspan="1" colspan="1">ND</td></tr><tr><td align="justify" rowspan="1" colspan="1"><bold><italic>ob/ob</italic> Li-10</bold></td><td align="justify" rowspan="1" colspan="1">54.3 &#x000b1; 1.8</td><td align="justify" rowspan="1" colspan="1">71.7 &#x000b1; 2.0</td><td align="justify" rowspan="1" colspan="1">79.2 &#x000b1; 3.0</td><td align="justify" rowspan="1" colspan="1">&#x0003c;0.25</td></tr><tr><td align="justify" style="border-bottom:thick" rowspan="1" colspan="1"><bold><italic>ob/ob</italic> Li-40</bold></td><td align="justify" style="border-bottom:thick" rowspan="1" colspan="1">53.8 &#x000b1; 1.5</td><td align="justify" style="border-bottom:thick" rowspan="1" colspan="1">72.4 &#x000b1; 1.9</td><td align="justify" style="border-bottom:thick" rowspan="1" colspan="1">78.7 &#x000b1;2.0</td><td align="justify" style="border-bottom:thick" rowspan="1" colspan="1">0.48 &#x000b1; 0.04</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>12-week old female BTBR-WT and -<italic>ob/ob</italic> mice received standard chow or chow with lithium supplementation (10 or 40 LiCl/kg) for 12 weeks. Lower detection range of the lithium analyser was 0.25 mM.</p></fn><fn id="t001fn002"><p>***p&#x0003c;0.001 vs. WT.</p></fn><fn id="t001fn003"><p>ND, not determined.</p></fn></table-wrap-foot></table-wrap><p>To determine the effect of lithium on DM2 itself, a glucose tolerance test was performed after 10 weeks of lithium treatment. Following fasting for 4 hours, blood glucose levels were increased in the <italic>ob/ob</italic> mice, which were not affected by lithium (<xref ref-type="fig" rid="pone.0189485.g002">Fig 2A</xref>). Then, following an intraperitoneal glucose injection, the mice were subjected to a glucose tolerance test. At 15 minutes after injection, blood glucose levels were strongly elevated in the <italic>ob/ob</italic> mice as compared to WT controls, while lithium attenuated this elevation (<xref ref-type="fig" rid="pone.0189485.g002">Fig 2A</xref>). Notably, blood glucose levels in <italic>ob/ob</italic> mice at 30, 60 and 120 minutes were mostly above the upper detection limit of the glucose meter (<xref ref-type="supplementary-material" rid="pone.0189485.s007">S2 Table</xref>), precluding further information. At the time of sacrifice, non-fasting blood glucose levels were determined. <italic>Ob/ob</italic> mice also exhibited elevated non-fasting blood glucose, which was reduced in the lithium-treated mice (<xref ref-type="fig" rid="pone.0189485.g002">Fig 2B</xref>). In fact, blood glucose levels of the <italic>ob/ob</italic> mice on Li-40 diet were similar to those of the WT controls. In line with an increased glucose uptake and tolerance with GSK inhibition, the non-fasting insulin levels were elevated in <italic>ob/ob</italic> mice as compared to WT mice, and tended to decrease (p = 0.14) in the mice on the Li-40 diet (<xref ref-type="fig" rid="pone.0189485.g002">Fig 2C</xref>).</p><fig id="pone.0189485.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0189485.g002</object-id><label>Fig 2</label><caption><title>The effect of lithium on blood glucose and insulin levels.</title><p>12-week old female BTBR-WT and -<italic>ob/ob</italic> mice received standard chow or chow with lithium supplementation (10 or 40 mmol LiCl/kg) for 12 weeks. Two weeks before sacrifice, mice were fasted for 4 hours, after which they received an intraperitoneal injection of 2 mg glucose/g bodyweight. Blood was collected before and 15 minutes after injection and blood glucose levels were determined (A). At the time of sacrifice blood was collected to analyze non-fasting (B) glucose and (C) insulin levels, n = 9 per group. *p&#x0003c;0.05; **p&#x0003c;0.01; ***p&#x0003c;0.001.</p></caption><graphic xlink:href="pone.0189485.g002"/></fig></sec><sec id="sec014"><title>Lithium increases urinary albumin and IgG content in BTBR-ob/ob mice</title><p>To establish the effect of lithium on diabetic nephropathy, we analysed the mice for GFR by inulin clearance, blood urea nitrogen (BUN) and ACR. After correction for bodyweight, thereby correcting for differences in kidney size,[<xref rid="pone.0189485.ref039" ref-type="bibr">39</xref>] GFR was not statistically different between the four groups (<xref ref-type="fig" rid="pone.0189485.g003">Fig 3A</xref>). There was also no significant difference in BUN between the groups, although it tended to increase in the <italic>ob/ob</italic> mice (p = 0.15) and tended to attenuate again with lithium (p = 0.42) (<xref ref-type="fig" rid="pone.0189485.g003">Fig 3B</xref>). ACR, determined from spot urine isolated at 12 weeks of treatment, was elevated in <italic>ob/ob</italic>-Ctr mice compared to WT mice. Importantly, lithium treatment increased ACR, which was significant in the Li-40 diet group (<xref ref-type="fig" rid="pone.0189485.g003">Fig 3C</xref>). Finally, spot urine was also analysed for the presence of immunoglobulin G (IgG), which is only found in urine when the filtration barrier is damaged.[<xref rid="pone.0189485.ref040" ref-type="bibr">40</xref>, <xref rid="pone.0189485.ref041" ref-type="bibr">41</xref>] Urinary IgG levels were significantly increased in <italic>ob/ob</italic> mice as compared to WT controls, which were aggravated by both the Li-10 and Li-40 diet (<xref ref-type="fig" rid="pone.0189485.g003">Fig 3D</xref>).</p><fig id="pone.0189485.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0189485.g003</object-id><label>Fig 3</label><caption><title>The effect of lithium on GFR, BUN, and urinary albumin and IgG levels.</title><p>12-week old female BTBR-WT and -ob/ob mice received standard chow or chow with lithium supplementation (10 or 40 mmol LiCl/kg) for 12 weeks. After 11 weeks of treatment, mice received a FITC-inulin bolus injection. Inulin clearance was determined via the decay of FITC-inulin in blood (A). At the time of sacrifice, blood was isolated and BUN was determined (B), while spot urine was collected earlier that week to determine (C) albumin-creatinine ratio and (D) IgG content, n = 9 per group. *p&#x0003c;0.05; ***p&#x0003c;0.001; ACR, albumin-creatinine ratio.</p></caption><graphic xlink:href="pone.0189485.g003"/></fig></sec><sec id="sec015"><title>Lithium-induced aggravation of albuminuria is likely not caused by glomerular damage</title><p>Both albumin and IgG levels are elevated in the urine of <italic>ob/ob</italic>-Ctr mice as compared to WT mice, indicating that the glomerular filtration barrier is damaged in the obese mice. The further elevation of urinary albumin and IgG levels upon lithium treatment might be due to further deterioration of glomerular function, but might also result from injury to the proximal tubule, as both albumin and IgG are reabsorbed by the proximal tubules following filtration leakage.[<xref rid="pone.0189485.ref042" ref-type="bibr">42</xref>] To investigate the origin of the increased urinary albumin and IgG levels in the lithium treated <italic>ob/ob</italic> mice, we first assessed the extent of mesangial matrix expansion using PAS staining (<xref ref-type="fig" rid="pone.0189485.g004">Fig 4A&#x02013;4C</xref>). In line with the elevated urinary albumin and IgG levels, <italic>ob/ob</italic>-Ctr mice demonstrated significantly more glomeruli with moderate and severe mesangial matrix expansion as compared to WT mice (<xref ref-type="fig" rid="pone.0189485.g004">Fig 4D and 4E</xref>). Interestingly, the number of moderately-affected glomeruli was reduced in the Li-40 group, while no significant differences were found with the other groups (<xref ref-type="fig" rid="pone.0189485.g004">Fig 4D and 4E</xref>). To obtain additional information on the abundance of podocytes, which form the filtration barrier, we next analysed our kidney samples for mRNA and protein levels of proteins that are characteristic for podocytes. However, podocin, nephrin, synaptopodin and podoplanin mRNAs levels were not affected by lithium (<xref ref-type="supplementary-material" rid="pone.0189485.s001">S1 Fig</xref>). Moreover, immunoblotting revealed that the abundance of nephrin was significantly reduced in the <italic>ob/ob</italic>-Ctr mice as compared to WT mice, which seemed to reverse in the Li-40 group, but this was not significant (p = 0.33) (<xref ref-type="fig" rid="pone.0189485.g004">Fig 4F and 4G</xref>). The nephrin immunoblotting was specific, because only one band around the predicted mass (180 kDa) was detected, which was observed in samples derived from the cortex, but not medulla (<xref ref-type="supplementary-material" rid="pone.0189485.s002">S2 Fig</xref>).</p><fig id="pone.0189485.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0189485.g004</object-id><label>Fig 4</label><caption><title>Analysis of glomerular injury upon lithium treatment.</title><p>12-week old female BTBR-WT and -<italic>ob/ob</italic> mice received standard chow or chow with lithium supplementation (10 or 40 LiCl mmol/kg) for 12 weeks. After sacrifice, kidneys were isolated and the absence (A) or presence of moderate (B) or severe (C) mesangial matrix expansion was determined using PAS staining. Moderate and severe mesangial matrix expansion was defined as an increased presence of mesangial matrix (indicated by stars) with the moderate form still having some open capillary lumens (indicated by arrows) while these are basically absent in the severe form. Scale bar indicates 10 &#x003bc;M. The percentage of glomeruli with moderate or severe mesangial matrix expansion was scored as follows: 0) 0&#x02013;1%, 1) 1&#x02013;5%, 2) 5&#x02013;20%, 3) 20&#x02013;50%, 4) &#x0003e;50% (D and E), n = 9 per group. Kidney lysates were used to determine nephrin abundance via immunoblotting (F) and subsequent semi-quantification (G), n = 9 per group. *p&#x0003c;0.05; ***p&#x0003c;0.001. Cm, Coomassie.</p></caption><graphic xlink:href="pone.0189485.g004"/></fig></sec><sec id="sec016"><title>Lithium may affect proximal tubular function</title><p>As proximal tubules reabsorb both albumin and IgG[<xref rid="pone.0189485.ref043" ref-type="bibr">43</xref>] in case of a damaged renal filter, we also tested whether dysfunction of this segment due to lithium may have caused the elevated urinary albumin and IgG levels observed with lithium. However, immunoblotting for megalin and cubilin, which are essential for albumin reabsorption in proximal tubules, revealed no differences between control and lithium-treated <italic>ob/ob</italic> mice (<xref ref-type="fig" rid="pone.0189485.g005">Fig 5A and 5B</xref>). To further investigate potential lithium-induced damage to the proximal tubule, we analysed the urinary activity and abundance of two different proximal tubule damage markers, being N-Acetylglucosaminidase (NAG) and serum neutrophil gelatinase associated lipocalin-2 (NGAL), respectively. While urinary NAG activity was not different between the groups (<xref ref-type="fig" rid="pone.0189485.g005">Fig 5C</xref>), urinary NGAL levels were significantly elevated by lithium (<xref ref-type="fig" rid="pone.0189485.g005">Fig 5D</xref>). Finally, the proximal brush border was stained using periodic acid-Schiff (PAS), as its disappearance indicates proximal tubule damage, as also found in early stages of diabetic nephropathy[<xref rid="pone.0189485.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0189485.ref045" ref-type="bibr">45</xref>]. In <italic>ob/ob</italic> mice the number of renal tubular epithelia with a reduced PAS staining in the brush border was increased as compared to WT mice, which was not significantly affected by lithium (<xref ref-type="fig" rid="pone.0189485.g005">Fig 5E and 5F</xref>). Finally, we performed some additional analyses to better understand the effects of lithium application in diabetic nephropathy. Using Picro Sirius Red staining, interstitial fibrosis was scored as absent, minimal or mild (<xref ref-type="supplementary-material" rid="pone.0189485.s003">S3A&#x02013;S3C Fig</xref>). No differences were found between groups (<xref ref-type="supplementary-material" rid="pone.0189485.s003">S3D Fig</xref>). Furthermore, cortical mRNA levels of &#x003b1;SMA, CTGF, TGF&#x003b2; and different inflammation markers were assessed. While no significant differences were found for the various inflammatory markers (<xref ref-type="supplementary-material" rid="pone.0189485.s004">S4 Fig</xref>), lithium partially reversed CTGF mRNA levels, but did not significantly reduce the increased &#x003b1;SMA levels in the ob/ob-Ctr mice, as compared to WT (<xref ref-type="fig" rid="pone.0189485.g006">Fig 6</xref>). No significant differences were found in TGF&#x003b2; mRNA levels (<xref ref-type="fig" rid="pone.0189485.g006">Fig 6</xref>).</p><fig id="pone.0189485.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0189485.g005</object-id><label>Fig 5</label><caption><title>Analysis of proximal tubule injury upon lithium treatment.</title><p>12-week old female BTBR-WT and -<italic>ob/ob</italic> mice received standard chow or chow with lithium supplementation (10 or 40 LiCl/kg) for 12 weeks. Kidney lysates were used to immunoblot for megalin (A) and cubilin (B) abundance, as shown by representative images in the upper panels, and subsequent densitometric analysis in lower panels (n = 9/group). Arrows indicate the 600-kDa bands for megalin and 460-kDa band for cubilin. Spot urine, collected in the week before sacrifice, was used to determine NAG activity (C) and NGAL (D) levels. Kidney sections were stained with PAS to determine brush border damage in the different groups, as is shown in the representative pictures (E). The scale bar represents 50 &#x003bc;M. The presence of brush border damage was scored as follows: 0) none, 1) minimal, 2) mild, 3) moderate and 4) severe (F). *p&#x0003c;0.05; ***p&#x0003c;0.001. Cm, Coomassie.</p></caption><graphic xlink:href="pone.0189485.g005"/></fig><fig id="pone.0189485.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0189485.g006</object-id><label>Fig 6</label><caption><title>The effect of lithium on cortical &#x003b1;SMA, CTGF and TGF&#x003b2; mRNA levels.</title><p>12-week old female BTBR-WT and -<italic>ob/ob</italic> mice received standard chow or chow with lithium supplementation (10 or 40 LiCl/kg) for 12 weeks. After RNA isolation from cortex, mRNA levels of (A) &#x003b1;SMA, (B) CTGF and (C) TGF&#x003b2; were determined by qPCR using 36B4 as a housekeeping gene. *p&#x0003c;0.05; **p&#x0003c;0.01.</p></caption><graphic xlink:href="pone.0189485.g006"/></fig></sec></sec><sec sec-type="conclusions" id="sec017"><title>Discussion</title><sec id="sec018"><title>Lithium reduces blood glucose levels via mechanisms likely involving insulin signaling</title><p>This study demonstrated that low lithium doses attenuate non-fasting blood glucose in BTBR-<italic>ob/ob</italic> mice, while fasting blood glucose was not affected. These low lithium doses (10 and 40 mmol/kg food) resulted in blood lithium levels of respectively &#x0003c;0.25 mM and 0.48 mM, which are both below the clinically used blood lithium concentration used to treat bipolar patients (0.6&#x02013;1.0 mM). Interestingly, daily administration of 100 mg of lithium carbonate in diabetic patients, which is a ~10-fold lower dose as normally administered to bipolar patients, also caused a reduction in postprandial blood glucose levels, while fasting blood glucose levels were not affected.[<xref rid="pone.0189485.ref034" ref-type="bibr">34</xref>] In agreement, other studies demonstrate that the beneficial effect of lithium on blood glucose handling only occurs in presence of insulin.[<xref rid="pone.0189485.ref034" ref-type="bibr">34</xref>, <xref rid="pone.0189485.ref046" ref-type="bibr">46</xref>] The precise mechanism by which lithium reduces blood glucose handling was not investigated in these studies although it likely involves its effect on GSK3 activity and subsequent regulation of IRS-1 and glycogen synthase. Thus, lithium likely enhances the efficacy of insulin during insulin resistance.[<xref rid="pone.0189485.ref046" ref-type="bibr">46</xref>, <xref rid="pone.0189485.ref047" ref-type="bibr">47</xref>] This lithium-insulin connection might explain why in our mouse study and in these diabetic patients lithium decreases blood glucose levels only in non-fasting conditions. In the latter situation, insulin levels are very low, as blood glucose levels are maintained via glycogenolysis, in which glucose is formed from glycogen.[<xref rid="pone.0189485.ref048" ref-type="bibr">48</xref>]</p></sec><sec id="sec019"><title>Lithium does not affect GFR in BTBR-ob/ob mice</title><p>To determine the effect of lithium on kidney injury in our diabetic mice, we first measured GFR, as this is also used to diagnose diabetic nephropathy in patients. For this, we assessed FITC-inulin clearance, as creatinine clearance is not a valid marker for GFR in mice.[<xref rid="pone.0189485.ref049" ref-type="bibr">49</xref>] Strikingly, the GFR of 24-week-old BTBR-<italic>ob/ob</italic> mice was similar to WT mice, despite overt glomerulosclerosis and albuminuria in the <italic>ob/ob</italic> mice. Also, both lithium diets did not affect GFR. It must be noted though, that GFR was calculated as inulin clearance per gram body weight, although other studies report GFR without correcting for body weight or by correcting for kidney weight.[<xref rid="pone.0189485.ref036" ref-type="bibr">36</xref>, <xref rid="pone.0189485.ref050" ref-type="bibr">50</xref>] As kidney weight was not determined by us, but has previously been shown to be increased by ~2-fold in BTBR-<italic>ob/ob</italic> mice as compared to WT mice,[<xref rid="pone.0189485.ref039" ref-type="bibr">39</xref>] we choose to correct for bodyweight, which was increased by 2.3 fold. Moreover, BUN levels were not statistically different between the groups but tended to increase in the <italic>ob/ob</italic> mice as compared to WT mice. These findings are in agreement with our GFR correction for bodyweight, as in comparison to WT mice, the <italic>ob/ob</italic> mice would have a hyperfiltration if not corrected for body weight, which would not be in agreement with their BUN levels. Altogether, it is likely that GFR is not yet affected in 24-week-old female BTBR-<italic>ob/ob</italic> mice, suggesting that this model represents a relative early stage of diabetic nephropathy in which a pronounced GFR decline is not yet present.</p></sec><sec id="sec020"><title>Lithium aggravates urinary albumin and IgG content in mice with diabetic nephropathy</title><p>As found previously, BTBR-<italic>ob/ob</italic> mice exhibited elevated urine albumin levels as compared to WT BTBR mice.[<xref rid="pone.0189485.ref011" ref-type="bibr">11</xref>] Additionally, we identified that the urine of the <italic>ob/ob</italic> mice contained significantly higher levels of IgG, indicating glomerular damage, as IgG is normally not filtered by the glomerulus.[<xref rid="pone.0189485.ref040" ref-type="bibr">40</xref>, <xref rid="pone.0189485.ref041" ref-type="bibr">41</xref>] Lithium further aggravated the urinary content of albumin and IgG. As both albumin and IgG are normally reabsorbed in the proximal tubule in case of filtration damage, this aggravation can result from deterioration of proximal tubule or glomerular function.[<xref rid="pone.0189485.ref042" ref-type="bibr">42</xref>] The latter did not seem affected, as the enhanced mesangial matrix expansion in the BTBR-<italic>ob/ob</italic> mice was decreased by lithium and the reduced nephrin abundance in the <italic>ob/ob</italic> mice was not further reduced by lithium, but even tended to be attenuated. Furthermore, mRNA levels of the typical podocyte proteins nephrin, podocin, podoplanin and synaptopodin were unchanged with lithium. Despite the absence of any indication of lithium-induced glomerular injury, we also did not yield strong evidence that lithium caused proximal tubule injury, as the protein abundance of megalin and cubilin, the receptors responsible for albumin uptake,[<xref rid="pone.0189485.ref042" ref-type="bibr">42</xref>] were not affected by lithium treatment. Moreover, NAG activity, a marker for proximal tubule injury, was also not significantly affected by lithium, although it tended to increase. Only urinary NGAL content was significantly elevated by lithium. Altogether, there is no strong evidence that lithium caused glomerular injury. As proximal tubule seemed to exhibit a little more damage in the lithium groups, the increased urinary albumin and IgG content most likely originates from proximal tubule injury. Although current results are not sufficient to establish the location of damage, a lithium-induced injury of proximal tubules would be more in line with data obtained in studies analysing the renotoxic effects of clinical lithium administration. Lithium-treated bipolar patients with CKD are characterized by the presence of tubular atrophy and interstitial fibrosis, while only a smaller part demonstrates glomerulosclerosis.[<xref rid="pone.0189485.ref051" ref-type="bibr">51</xref>] Also in rabbits it has been shown that lithium first causes tubular atrophy and interstitial fibrosis, while glomerulosclerosis develops much later in disease.[<xref rid="pone.0189485.ref052" ref-type="bibr">52</xref>] Altogether, our data indicate that administration of subclinical lithium dosi is likely not a good strategy to combat diabetic nephropathy.</p></sec><sec id="sec021"><title>Molecular mechanism underlying lithium-induced albuminuria remains elusive</title><p>We found that lithium increased urine albumin and IgG levels, however the molecular mechanism behind these observations was not identified. Most likely these effects of lithium involve GSK3 inhibition. It is known that GKS3 plays an important role in the function of proximal tubules and podocytes,[<xref rid="pone.0189485.ref053" ref-type="bibr">53</xref>, <xref rid="pone.0189485.ref054" ref-type="bibr">54</xref>] the most likely origins for albuminuria. By inhibiting GSK3, lithium might have directly affected the function of these cells. We found however that lithium did not increase GSK3 phosphorylation, an inhibitory modulation, in whole kidney lysates (<bold><xref ref-type="supplementary-material" rid="pone.0189485.s005">S5 Fig</xref></bold>). As such, lithium-induced albuminuria is most likely due to the direct inhibition of GSK3 by lithium via its competition for magnesium[<xref rid="pone.0189485.ref023" ref-type="bibr">23</xref>]. Alternatively, the increased urine albumin and IgG levels might be the consequence of the effects of lithium on blood glucose or insulin levels. While altered blood glucose levels affect both the glomerulus and proximal tubules, altered insulin levels would mainly affect podocyte function, as insulin receptors are present on these cells and were shown to play a role in filtration.[<xref rid="pone.0189485.ref039" ref-type="bibr">39</xref>] A role for direct GSK3 inhibition is however more likely as reduced blood glucose and insulin levels, as observed in this study, would rather lead to a reduction in albuminuria.[<xref rid="pone.0189485.ref039" ref-type="bibr">39</xref>] Future studies should aim to elucidate the molecular effects of lithium by analyzing the molecular effects in specific cell types of the kidney.</p></sec><sec id="sec022"><title>The application of lithium in bipolar patients with diabetes mellitus</title><p>Thus, although lithium is not likely to become a treatment for diabetic nephropathy, there are thousands of bipolar patients with DM who are treated with lithium for their bipolar disease. The precise effect of such higher lithium dose on kidney function in this subpopulation is not known, however a recent large retrospective analysis did not find an increased risk of CKD, determined by a decrease in eGFR, in lithium-using patients with DM as compared with lithium only.[<xref rid="pone.0189485.ref055" ref-type="bibr">55</xref>] However, the number of DM patients was rather small. Therefore, it would be worthwhile to compare renal decline in DM patients who are treated with lithium with those who are treated with other treatments for mental disease.</p></sec></sec><sec sec-type="supplementary-material" id="sec023"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0189485.s001"><label>S1 Fig</label><caption><title>The effect of lithium on mRNA levels of nephrin, podocin, podoplanin and synaptopodin.</title><p>12-week old female BTBR-WT and -<italic>ob/ob</italic> mice received standard chow or chow with lithium supplementation (10 or 40 LiCl/kg) for 12 weeks. After RNA isolation from cortex, mRNA levels of nephrin, podocin, podoplanin and synaptopodin were determined by qPCR using 36B4 as a housekeeping gene. *p&#x0003c;0.05.</p><p>(PDF)</p></caption><media xlink:href="pone.0189485.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0189485.s002"><label>S2 Fig</label><caption><title>The abundance of nephrin in rat cortex and outer medulla.</title><p>Cortex and medullary material from 3-month old Wistar rats were immunoblotted for nephrin. Cm, Coomassie.</p><p>(PDF)</p></caption><media xlink:href="pone.0189485.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0189485.s003"><label>S3 Fig</label><caption><title>The effect of lithium on interstitial fibrosis in BTBR-ob/ob mice.</title><p>12-week old female BTBR-WT and -<italic>ob/ob</italic> mice received standard chow or chow with lithium supplementation (10 or 40 LiCl mmol/kg) for 12 weeks. After sacrifice, kidneys were isolated and the absence (A) or presence of minimal (B) or mild (C) interstitial fibrosis was determined using Picro Sirius Red staining and (D) scored with respective scores of 0, 1 or 2. Minimal interstitial fibrosis was defined as the presence of fibrotic tissue in up to 20% of whole kidney. When this presence exceeded 20%, but was less than 40%, it was defined as mild. In none of the kidneys the presence of interstitial fibrosis extended 40% of the whole area.</p><p>(PDF)</p></caption><media xlink:href="pone.0189485.s003.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0189485.s004"><label>S4 Fig</label><caption><title>The effect of lithium on mRNA expression on various inflammatory markers.</title><p>12-week old female BTBR-WT and -<italic>ob/ob</italic> mice received standard chow or chow with lithium supplementation (10 or 40 LiCl/kg) for 12 weeks. After RNA isolation from cortex, mRNA levels of TNF&#x003b1;, IFNY, F4/80, CD68, MCP1 and IL-1RA were determined by qPCR using 36B4 as a housekeeping gene.</p><p>(PDF)</p></caption><media xlink:href="pone.0189485.s004.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0189485.s005"><label>S5 Fig</label><caption><title>pGSK3/GSK3 ratio in BTBR-<italic>ob/ob</italic> mice.</title><p>12-week old female BTBR- <italic>ob/ob</italic> mice received standard chow (Ctr) or chow with lithium supplementation (10 or 40 LiCl/kg). After 12 weeks kidneys were isolated and protein lysates were immunoblotted for pGSK3 and GSK3. Representative immunoblots for <italic>ob/ob</italic> mice for (A) GSK3 and (B) pGSK3 are depicted. Corresponding densitometric analysis of (C) total GSK3 abundance and pGSK3/GSK3 ratio (n = 5&#x02013;9 per group). Cm, Coomassie.</p><p>(PDF)</p></caption><media xlink:href="pone.0189485.s005.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0189485.s006"><label>S1 Table</label><caption><title>Primer sequences.</title><p>(PDF)</p></caption><media xlink:href="pone.0189485.s006.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0189485.s007"><label>S2 Table</label><caption><title>Blood glucose levels 30, 60 and 120 minutes after intraperitoneal glucose injection.</title><p>(PDF)</p></caption><media xlink:href="pone.0189485.s007.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We would like to thank Holly Savage, Yuka Tukamon, Thomas O'Rourke and Rita O'Rourke (from the Jackson Laboratory) for their expert help. The megalin and cubilin antibodies were a kind gift from Prof. Pierre Verroust, INSERM, Paris, France.</p></ack><ref-list><title>References</title><ref id="pone.0189485.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Radbill</surname><given-names>B</given-names></name>, <name><surname>Murphy</surname><given-names>B</given-names></name>, <name><surname>LeRoith</surname><given-names>D</given-names></name>. <article-title>Rationale and strategies for early detection and management of diabetic kidney disease</article-title>. <source>Mayo Clinic proceedings</source>. <year>2008</year>;<volume>83</volume>(<issue>12</issue>):<fpage>1373</fpage>&#x02013;<lpage>81</lpage>. Epub 2008/12/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0025-6196(11)60786-6">10.1016/S0025-6196(11)60786-6</ext-link></comment> .<pub-id pub-id-type="pmid">19046557</pub-id></mixed-citation></ref><ref id="pone.0189485.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>Y-M</given-names></name>, <name><surname>Su</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>L-F</given-names></name>. <article-title>Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy</article-title>. <source>Biochemical and biophysical research communications</source>. <year>2013</year>;<volume>433</volume>(<issue>4</issue>):<fpage>359</fpage>&#x02013;<lpage>61</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbrc.2013.02.120">http://dx.doi.org/10.1016/j.bbrc.2013.02.120</ext-link>. <pub-id pub-id-type="pmid">23541575</pub-id></mixed-citation></ref><ref id="pone.0189485.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Galkina</surname><given-names>E</given-names></name>, <name><surname>Ley</surname><given-names>K</given-names></name>. <article-title>Leukocyte recruitment and vascular injury in diabetic nephropathy</article-title>. <source>Journal of the American Society of Nephrology: JASN</source>. <year>2006</year>;<volume>17</volume>(<issue>2</issue>):<fpage>368</fpage>&#x02013;<lpage>77</lpage>. Epub 2006/01/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1681/ASN.2005080859">10.1681/ASN.2005080859</ext-link></comment> .<pub-id pub-id-type="pmid">16394109</pub-id></mixed-citation></ref><ref id="pone.0189485.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Ha</surname><given-names>H</given-names></name>, <name><surname>Lee</surname><given-names>HB</given-names></name>. <article-title>Oxidative stress in diabetic nephropathy: basic and clinical information</article-title>. <source>Current diabetes reports</source>. <year>2001</year>;<volume>1</volume>(<issue>3</issue>):<fpage>282</fpage>&#x02013;<lpage>7</lpage>. Epub 2003/03/20. .<pub-id pub-id-type="pmid">12643211</pub-id></mixed-citation></ref><ref id="pone.0189485.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Rudberg</surname><given-names>S</given-names></name>, <name><surname>Osterby</surname><given-names>R</given-names></name>. <article-title>Decreasing glomerular filtration rate&#x02014;an indicator of more advanced diabetic glomerulopathy in the early course of microalbuminuria in IDDM adolescents?</article-title>
<source>Nephrology Dialysis Transplantation</source>. <year>1997</year>;<volume>12</volume>(<issue>6</issue>):<fpage>1149</fpage>&#x02013;<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/ndt/12.6.1149">10.1093/ndt/12.6.1149</ext-link></comment></mixed-citation></ref><ref id="pone.0189485.ref006"><label>6</label><mixed-citation publication-type="journal"><collab>2012 GK</collab>. <article-title>KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease</article-title>. <source>Kidney Int</source>. <year>2012</year>;<volume>3</volume> (suppl 2013)(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>150</lpage>.</mixed-citation></ref><ref id="pone.0189485.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>CH</given-names></name>, <name><surname>Noh</surname><given-names>JS</given-names></name>, <name><surname>Tanaka</surname><given-names>T</given-names></name>, <name><surname>Yokozawa</surname><given-names>T</given-names></name>. <article-title>7-O-galloyl-D-sedoheptulose ameliorates renal damage triggered by reactive oxygen species-sensitive pathway of inflammation and apoptosis</article-title>. <source>The Journal of pharmacy and pharmacology</source>. <year>2012</year>;<volume>64</volume>(<issue>12</issue>):<fpage>1730</fpage>&#x02013;<lpage>40</lpage>. Epub 2012/11/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.2042-7158.2012.01559.x">10.1111/j.2042-7158.2012.01559.x</ext-link></comment> .<pub-id pub-id-type="pmid">23146036</pub-id></mixed-citation></ref><ref id="pone.0189485.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Alsaad</surname><given-names>KO</given-names></name>, <name><surname>Herzenberg</surname><given-names>AM</given-names></name>. <article-title>Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update</article-title>. <source>Journal of Clinical Pathology</source>. <year>2007</year>;<volume>60</volume>(<issue>1</issue>):<fpage>18</fpage>&#x02013;<lpage>26</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/jcp.2005.035592">10.1136/jcp.2005.035592</ext-link></comment> ; PubMed Central PMCID: PMCPmc1860608.<pub-id pub-id-type="pmid">17213346</pub-id></mixed-citation></ref><ref id="pone.0189485.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Brosnahan</surname><given-names>G</given-names></name>, <name><surname>Fraer</surname><given-names>M</given-names></name>. <article-title>Chronic kidney disease: whom to screen and how to treat, part 1: definition, epidemiology, and laboratory testing</article-title>. <source>Southern medical journal</source>. <year>2010</year>;<volume>103</volume>(<issue>2</issue>):<fpage>140</fpage>&#x02013;<lpage>6</lpage>. Epub 2010/01/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/SMJ.0b013e3181c99438">10.1097/SMJ.0b013e3181c99438</ext-link></comment> .<pub-id pub-id-type="pmid">20065899</pub-id></mixed-citation></ref><ref id="pone.0189485.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Gross</surname><given-names>JL</given-names></name>, <name><surname>de Azevedo</surname><given-names>MJ</given-names></name>, <name><surname>Silveiro</surname><given-names>SP</given-names></name>, <name><surname>Canani</surname><given-names>LH</given-names></name>, <name><surname>Caramori</surname><given-names>ML</given-names></name>, <name><surname>Zelmanovitz</surname><given-names>T</given-names></name>. <article-title>Diabetic nephropathy: diagnosis, prevention, and treatment</article-title>. <source>Diabetes care</source>. <year>2005</year>;<volume>28</volume>(<issue>1</issue>):<fpage>164</fpage>&#x02013;<lpage>76</lpage>. Epub 2004/12/24. .<pub-id pub-id-type="pmid">15616252</pub-id></mixed-citation></ref><ref id="pone.0189485.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Hudkins</surname><given-names>KL</given-names></name>, <name><surname>Pichaiwong</surname><given-names>W</given-names></name>, <name><surname>Wietecha</surname><given-names>T</given-names></name>, <name><surname>Kowalewska</surname><given-names>J</given-names></name>, <name><surname>Banas</surname><given-names>MC</given-names></name>, <name><surname>Spencer</surname><given-names>MW</given-names></name>, <etal>et al</etal>
<article-title>BTBR Ob/Ob mutant mice model progressive diabetic nephropathy</article-title>. <source>J Am Soc Nephrol</source>. <year>2010</year>;<volume>21</volume>(<issue>9</issue>):<fpage>1533</fpage>&#x02013;<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1681/ASN.2009121290">10.1681/ASN.2009121290</ext-link></comment> .<pub-id pub-id-type="pmid">20634301</pub-id></mixed-citation></ref><ref id="pone.0189485.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Eknoyan</surname><given-names>G</given-names></name>, <name><surname>Lameire</surname><given-names>N</given-names></name>, <name><surname>Eckardt</surname><given-names>K</given-names></name>, <name><surname>Kasiske</surname><given-names>B</given-names></name>, <name><surname>Wheeler</surname><given-names>D</given-names></name>, <name><surname>Levin</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease</article-title>. <source>Kidney Int</source>. <year>2013</year>;<volume>3</volume>:<fpage>5</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="pone.0189485.ref013"><label>13</label><mixed-citation publication-type="book"><collab>WHO</collab>. <chapter-title>Global report on diabetes</chapter-title>
<publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2016</year>.</mixed-citation></ref><ref id="pone.0189485.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Levey</surname><given-names>AS</given-names></name>, <name><surname>Coresh</surname><given-names>J</given-names></name>. <article-title>Chronic kidney disease</article-title>. <source>Lancet (London, England)</source>. <year>2012</year>;<volume>379</volume>(<issue>9811</issue>):<fpage>165</fpage>&#x02013;<lpage>80</lpage>. Epub 2011/08/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/s0140-6736(11)60178-5">10.1016/s0140-6736(11)60178-5</ext-link></comment> .<pub-id pub-id-type="pmid">21840587</pub-id></mixed-citation></ref><ref id="pone.0189485.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Henriksen</surname><given-names>EJ</given-names></name>, <name><surname>Dokken</surname><given-names>BB</given-names></name>. <article-title>Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes</article-title>. <source>Curr Drug Targets</source>. <year>2006</year>;<volume>7</volume>(<issue>11</issue>):<fpage>1435</fpage>&#x02013;<lpage>41</lpage>. .<pub-id pub-id-type="pmid">17100583</pub-id></mixed-citation></ref><ref id="pone.0189485.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Eldar-Finkelman</surname><given-names>H</given-names></name>, <name><surname>Krebs</surname><given-names>EG</given-names></name>. <article-title>Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>1997</year>;<volume>94</volume>(<issue>18</issue>):<fpage>9660</fpage>&#x02013;<lpage>4</lpage>. Epub 1997/09/02. ; PubMed Central PMCID: PMCPmc23245.<pub-id pub-id-type="pmid">9275179</pub-id></mixed-citation></ref><ref id="pone.0189485.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Thiebaud</surname><given-names>D</given-names></name>, <name><surname>Jacot</surname><given-names>E</given-names></name>, <name><surname>DeFronzo</surname><given-names>RA</given-names></name>, <name><surname>Maeder</surname><given-names>E</given-names></name>, <name><surname>Jequier</surname><given-names>E</given-names></name>, <name><surname>Felber</surname><given-names>JP</given-names></name>. <article-title>The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man</article-title>. <source>Diabetes</source>. <year>1982</year>;<volume>31</volume>(<issue>11</issue>):<fpage>957</fpage>&#x02013;<lpage>63</lpage>. Epub 1982/11/01. .<pub-id pub-id-type="pmid">6757014</pub-id></mixed-citation></ref><ref id="pone.0189485.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>P</given-names></name>, <name><surname>Goedert</surname><given-names>M</given-names></name>. <article-title>GSK3 inhibitors: development and therapeutic potential</article-title>. <source>Nature reviews Drug discovery</source>. <year>2004</year>;<volume>3</volume>(<issue>6</issue>):<fpage>479</fpage>&#x02013;<lpage>87</lpage>. Epub 2004/06/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrd1415">10.1038/nrd1415</ext-link></comment> .<pub-id pub-id-type="pmid">15173837</pub-id></mixed-citation></ref><ref id="pone.0189485.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Patel</surname><given-names>S</given-names></name>, <name><surname>Doble</surname><given-names>BW</given-names></name>, <name><surname>MacAulay</surname><given-names>K</given-names></name>, <name><surname>Sinclair</surname><given-names>EM</given-names></name>, <name><surname>Drucker</surname><given-names>DJ</given-names></name>, <name><surname>Woodgett</surname><given-names>JR</given-names></name>. <article-title>Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action</article-title>. <source>Molecular and cellular biology</source>. <year>2008</year>;<volume>28</volume>(<issue>20</issue>):<fpage>6314</fpage>&#x02013;<lpage>28</lpage>. Epub 2008/08/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/MCB.00763-08">10.1128/MCB.00763-08</ext-link></comment> ; PubMed Central PMCID: PMCPmc2577415.<pub-id pub-id-type="pmid">18694957</pub-id></mixed-citation></ref><ref id="pone.0189485.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Jope</surname><given-names>RS</given-names></name>. <article-title>Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes</article-title>. <source>Trends in pharmacological sciences</source>. <year>2003</year>;<volume>24</volume>(<issue>9</issue>):<fpage>441</fpage>&#x02013;<lpage>3</lpage>. Epub 2003/09/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0165-6147(03)00206-2">10.1016/S0165-6147(03)00206-2</ext-link></comment> .<pub-id pub-id-type="pmid">12967765</pub-id></mixed-citation></ref><ref id="pone.0189485.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Nikoulina</surname><given-names>SE</given-names></name>, <name><surname>Ciaraldi</surname><given-names>TP</given-names></name>, <name><surname>Mudaliar</surname><given-names>S</given-names></name>, <name><surname>Mohideen</surname><given-names>P</given-names></name>, <name><surname>Carter</surname><given-names>L</given-names></name>, <name><surname>Henry</surname><given-names>RR</given-names></name>. <article-title>Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes</article-title>. <source>Diabetes</source>. <year>2000</year>;<volume>49</volume>(<issue>2</issue>):<fpage>263</fpage>&#x02013;<lpage>71</lpage>. Epub 2000/06/27. .<pub-id pub-id-type="pmid">10868943</pub-id></mixed-citation></ref><ref id="pone.0189485.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>New</surname><given-names>LA</given-names></name>, <name><surname>Martin</surname><given-names>CE</given-names></name>, <name><surname>Scott</surname><given-names>RP</given-names></name>, <name><surname>Platt</surname><given-names>MJ</given-names></name>, <name><surname>Keyvani Chahi</surname><given-names>A</given-names></name>, <name><surname>Stringer</surname><given-names>CD</given-names></name>, <etal>et al</etal>
<article-title>Nephrin Tyrosine Phosphorylation Is Required to Stabilize and Restore Podocyte Foot Process Architecture</article-title>. <source>J Am Soc Nephrol</source>. <year>2016</year>;<volume>27</volume>(<issue>8</issue>):<fpage>2422</fpage>&#x02013;<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1681/ASN.2015091048">10.1681/ASN.2015091048</ext-link></comment> ; PubMed Central PMCID: PMC4978059.<pub-id pub-id-type="pmid">26802179</pub-id></mixed-citation></ref><ref id="pone.0189485.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Ryves</surname><given-names>WJ</given-names></name>, <name><surname>Harwood</surname><given-names>AJ</given-names></name>. <article-title>Lithium inhibits glycogen synthase kinase-3 by competition for magnesium</article-title>. <source>Biochemical and biophysical research communications</source>. <year>2001</year>;<volume>280</volume>(<issue>3</issue>):<fpage>720</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1006/bbrc.2000.4169">10.1006/bbrc.2000.4169</ext-link></comment> .<pub-id pub-id-type="pmid">11162580</pub-id></mixed-citation></ref><ref id="pone.0189485.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Henriksen</surname><given-names>EJ</given-names></name>, <name><surname>Dokken</surname><given-names>BB</given-names></name>. <article-title>Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes</article-title>. <source>Current drug targets</source>. <year>2006</year>;<volume>7</volume>(<issue>11</issue>):<fpage>1435</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="pmid">17100583</pub-id></mixed-citation></ref><ref id="pone.0189485.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Tanabe</surname><given-names>K</given-names></name>, <name><surname>Liu</surname><given-names>Z</given-names></name>, <name><surname>Patel</surname><given-names>S</given-names></name>, <name><surname>Doble</surname><given-names>BW</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Cras-Meneur</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance</article-title>. <source>PLoS Biol</source>. <year>2008</year>;<volume>6</volume>(<issue>2</issue>):<fpage>e37</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pbio.0060037">10.1371/journal.pbio.0060037</ext-link></comment> .<pub-id pub-id-type="pmid">18288891</pub-id></mixed-citation></ref><ref id="pone.0189485.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Eldar-Finkelman</surname><given-names>H</given-names></name>, <name><surname>Schreyer</surname><given-names>SA</given-names></name>, <name><surname>Shinohara</surname><given-names>MM</given-names></name>, <name><surname>LeBoeuf</surname><given-names>RC</given-names></name>, <name><surname>Krebs</surname><given-names>EG</given-names></name>. <article-title>Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice</article-title>. <source>Diabetes</source>. <year>1999</year>;<volume>48</volume>(<issue>8</issue>):<fpage>1662</fpage>&#x02013;<lpage>6</lpage>. Epub 1999/07/30. .<pub-id pub-id-type="pmid">10426388</pub-id></mixed-citation></ref><ref id="pone.0189485.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Oetjen</surname><given-names>S</given-names></name>, <name><surname>Mahlke</surname><given-names>C</given-names></name>, <name><surname>Hermans-Borgmeyer</surname><given-names>I</given-names></name>, <name><surname>Hermey</surname><given-names>G</given-names></name>. <article-title>Spatiotemporal expression analysis of the growth factor receptor SorCS3</article-title>. <source>The Journal of comparative neurology</source>. <year>2014</year>;<volume>522</volume>(<issue>15</issue>):<fpage>3386</fpage>&#x02013;<lpage>402</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/cne.23606">10.1002/cne.23606</ext-link></comment> .<pub-id pub-id-type="pmid">24715575</pub-id></mixed-citation></ref><ref id="pone.0189485.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Bao</surname><given-names>H</given-names></name>, <name><surname>Ge</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Zhuang</surname><given-names>S</given-names></name>, <name><surname>Dworkin</surname><given-names>L</given-names></name>, <name><surname>Peng</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Delayed administration of a single dose of lithium promotes recovery from AKI</article-title>. <source>J Am Soc Nephrol</source>. <year>2014</year>;<volume>25</volume>(<issue>3</issue>):<fpage>488</fpage>&#x02013;<lpage>500</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1681/ASN.2013040350">10.1681/ASN.2013040350</ext-link></comment> .<pub-id pub-id-type="pmid">24408869</pub-id></mixed-citation></ref><ref id="pone.0189485.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Bao</surname><given-names>H</given-names></name>, <name><surname>Ge</surname><given-names>Y</given-names></name>, <name><surname>Peng</surname><given-names>A</given-names></name>, <name><surname>Gong</surname><given-names>R</given-names></name>. <article-title>Fine-tuning of NFkappaB by glycogen synthase kinase 3beta directs the fate of glomerular podocytes upon injury</article-title>. <source>Kidney international</source>. <year>2015</year>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ki.2014.428">10.1038/ki.2014.428</ext-link></comment> .<pub-id pub-id-type="pmid">25629551</pub-id></mixed-citation></ref><ref id="pone.0189485.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Ge</surname><given-names>Y</given-names></name>, <name><surname>Bao</surname><given-names>H</given-names></name>, <name><surname>Dworkin</surname><given-names>L</given-names></name>, <name><surname>Peng</surname><given-names>A</given-names></name>, <name><surname>Gong</surname><given-names>R</given-names></name>. <article-title>Redox-sensitive glycogen synthase kinase 3beta-directed control of mitochondrial permeability transition: rheostatic regulation of acute kidney injury</article-title>. <source>Free Radic Biol Med</source>. <year>2013</year>;<volume>65</volume>:<fpage>849</fpage>&#x02013;<lpage>58</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.freeradbiomed.2013.08.169">10.1016/j.freeradbiomed.2013.08.169</ext-link></comment> .<pub-id pub-id-type="pmid">23973862</pub-id></mixed-citation></ref><ref id="pone.0189485.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Boini</surname><given-names>KM</given-names></name>, <name><surname>Amann</surname><given-names>K</given-names></name>, <name><surname>Kempe</surname><given-names>D</given-names></name>, <name><surname>Alessi</surname><given-names>DR</given-names></name>, <name><surname>Lang</surname><given-names>F</given-names></name>. <article-title>Proteinuria in mice expressing PKB/SGK-resistant GSK3</article-title>. <source>Am J Physiol Renal Physiol</source>. <year>2009</year>;<volume>296</volume>(<issue>1</issue>):<fpage>F153</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/ajprenal.90398.2008">10.1152/ajprenal.90398.2008</ext-link></comment> .<pub-id pub-id-type="pmid">18987114</pub-id></mixed-citation></ref><ref id="pone.0189485.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Goodwin</surname><given-names>FK</given-names></name>. <article-title>Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment</article-title>. <source>The Journal of clinical psychiatry</source>. <year>2002</year>;<volume>63</volume>
<issue>Suppl 10</issue>:<fpage>5</fpage>&#x02013;<lpage>12</lpage>. Epub 2002/10/24. .<pub-id pub-id-type="pmid">12392347</pub-id></mixed-citation></ref><ref id="pone.0189485.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>de Groot</surname><given-names>T</given-names></name>, <name><surname>Sinke</surname><given-names>AP</given-names></name>, <name><surname>Kortenoeven</surname><given-names>ML</given-names></name>, <name><surname>Alsady</surname><given-names>M</given-names></name>, <name><surname>Baumgarten</surname><given-names>R</given-names></name>, <name><surname>Devuyst</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>Acetazolamide Attenuates Lithium-Induced Nephrogenic Diabetes Insipidus</article-title>. <source>J Am Soc Nephrol</source>. <year>2016</year>;<volume>27</volume>(<issue>7</issue>):<fpage>2082</fpage>&#x02013;<lpage>91</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1681/ASN.2015070796">10.1681/ASN.2015070796</ext-link></comment> ; PubMed Central PMCID: PMC4926986.<pub-id pub-id-type="pmid">26574046</pub-id></mixed-citation></ref><ref id="pone.0189485.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>M</given-names></name>, <name><surname>Wu</surname><given-names>H</given-names></name>, <name><surname>Chao</surname><given-names>C</given-names></name>. <article-title>Assisting effects of lithium on hypoglycemic treatment in patients with diabetes</article-title>. <source>Biol Trace Elem Res</source>. <year>1997</year>;<volume>60</volume>(<issue>1&#x02013;2</issue>):<fpage>131</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/BF02783316">10.1007/BF02783316</ext-link></comment> .<pub-id pub-id-type="pmid">9404682</pub-id></mixed-citation></ref><ref id="pone.0189485.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Cogan</surname><given-names>MG</given-names></name>, <name><surname>Maddox</surname><given-names>DA</given-names></name>, <name><surname>Warnock</surname><given-names>DG</given-names></name>, <name><surname>Lin</surname><given-names>ET</given-names></name>, <name><surname>Rector</surname><given-names>FC</given-names></name>, <article-title>Jr. Effect of acetazolamide on bicarbonate reabsorption in the proximal tubule of the rat</article-title>. <source>Am J Physiol</source>. <year>1979</year>;<volume>237</volume>(<issue>6</issue>):<fpage>F447</fpage>&#x02013;<lpage>54</lpage>. .<pub-id pub-id-type="pmid">517658</pub-id></mixed-citation></ref><ref id="pone.0189485.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Qi</surname><given-names>Z</given-names></name>, <name><surname>Whitt</surname><given-names>I</given-names></name>, <name><surname>Mehta</surname><given-names>A</given-names></name>, <name><surname>Jin</surname><given-names>J</given-names></name>, <name><surname>Zhao</surname><given-names>M</given-names></name>, <name><surname>Harris</surname><given-names>RC</given-names></name>, <etal>et al</etal>
<article-title>Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance</article-title>. <source>American journal of physiology Renal physiology</source>. <year>2004</year>;<volume>286</volume>(<issue>3</issue>):<fpage>F590</fpage>&#x02013;<lpage>6</lpage>. Epub 2003/11/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/ajprenal.00324.2003">10.1152/ajprenal.00324.2003</ext-link></comment> .<pub-id pub-id-type="pmid">14600035</pub-id></mixed-citation></ref><ref id="pone.0189485.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Tsaih</surname><given-names>SW</given-names></name>, <name><surname>Pezzolesi</surname><given-names>MG</given-names></name>, <name><surname>Yuan</surname><given-names>R</given-names></name>, <name><surname>Warram</surname><given-names>JH</given-names></name>, <name><surname>Krolewski</surname><given-names>AS</given-names></name>, <name><surname>Korstanje</surname><given-names>R</given-names></name>. <article-title>Genetic analysis of albuminuria in aging mice and concordance with loci for human diabetic nephropathy found in a genome-wide association scan</article-title>. <source>Kidney international</source>. <year>2010</year>;<volume>77</volume>(<issue>3</issue>):<fpage>201</fpage>&#x02013;<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ki.2009.434">10.1038/ki.2009.434</ext-link></comment> .<pub-id pub-id-type="pmid">19924099</pub-id></mixed-citation></ref><ref id="pone.0189485.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>de Groot</surname><given-names>T</given-names></name>, <name><surname>Alsady</surname><given-names>M</given-names></name>, <name><surname>Jaklofsky</surname><given-names>M</given-names></name>, <name><surname>Otte-Holler</surname><given-names>I</given-names></name>, <name><surname>Baumgarten</surname><given-names>R</given-names></name>, <name><surname>Giles</surname><given-names>RH</given-names></name>, <etal>et al</etal>
<article-title>Lithium causes G2 arrest of renal principal cells</article-title>. <source>J Am Soc Nephrol</source>. <year>2014</year>;<volume>25</volume>(<issue>3</issue>):<fpage>501</fpage>&#x02013;<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1681/ASN.2013090988">10.1681/ASN.2013090988</ext-link></comment> .<pub-id pub-id-type="pmid">24408872</pub-id></mixed-citation></ref><ref id="pone.0189485.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Coward</surname><given-names>R</given-names></name>, <name><surname>Fornoni</surname><given-names>A</given-names></name>. <article-title>Insulin signaling: implications for podocyte biology in diabetic kidney disease</article-title>. <source>Current opinion in nephrology and hypertension</source>. <year>2015</year>;<volume>24</volume>(<issue>1</issue>):<fpage>104</fpage>&#x02013;<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/MNH.0000000000000078">10.1097/MNH.0000000000000078</ext-link></comment> ; PubMed Central PMCID: PMC4386894.<pub-id pub-id-type="pmid">25415617</pub-id></mixed-citation></ref><ref id="pone.0189485.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Cohen-Bucay</surname><given-names>A</given-names></name>, <name><surname>Viswanathan</surname><given-names>G</given-names></name>. <article-title>Urinary markers of glomerular injury in diabetic nephropathy</article-title>. <source>International journal of nephrology</source>. <year>2012</year>;<volume>2012</volume>:<fpage>146987</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2012/146987">10.1155/2012/146987</ext-link></comment> ; PubMed Central PMCID: PMC3356892.<pub-id pub-id-type="pmid">22645683</pub-id></mixed-citation></ref><ref id="pone.0189485.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Akilesh</surname><given-names>S</given-names></name>, <name><surname>Huber</surname><given-names>TB</given-names></name>, <name><surname>Wu</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>G</given-names></name>, <name><surname>Hartleben</surname><given-names>B</given-names></name>, <name><surname>Kopp</surname><given-names>JB</given-names></name>, <etal>et al</etal>
<article-title>Podocytes use FcRn to clear IgG from the glomerular basement membrane</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2008</year>;<volume>105</volume>(<issue>3</issue>):<fpage>967</fpage>&#x02013;<lpage>72</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.0711515105">10.1073/pnas.0711515105</ext-link></comment> ; PubMed Central PMCID: PMC2242706.<pub-id pub-id-type="pmid">18198272</pub-id></mixed-citation></ref><ref id="pone.0189485.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Dickson</surname><given-names>LE</given-names></name>, <name><surname>Wagner</surname><given-names>MC</given-names></name>, <name><surname>Sandoval</surname><given-names>RM</given-names></name>, <name><surname>Molitoris</surname><given-names>BA</given-names></name>. <article-title>The proximal tubule and albuminuria: really!</article-title>
<source>J Am Soc Nephrol</source>. <year>2014</year>;<volume>25</volume>(<issue>3</issue>):<fpage>443</fpage>&#x02013;<lpage>53</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1681/ASN.2013090950">10.1681/ASN.2013090950</ext-link></comment> ; PubMed Central PMCID: PMC3935594.<pub-id pub-id-type="pmid">24408874</pub-id></mixed-citation></ref><ref id="pone.0189485.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Nielsen</surname><given-names>R</given-names></name>, <name><surname>Christensen</surname><given-names>EI</given-names></name>, <name><surname>Birn</surname><given-names>H</given-names></name>. <article-title>Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease</article-title>. <source>Kidney international</source>. <year>2016</year>;<volume>89</volume>(<issue>1</issue>):<fpage>58</fpage>&#x02013;<lpage>67</lpage>. Epub 2016/01/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.kint.2015.11.007">10.1016/j.kint.2015.11.007</ext-link></comment> .<pub-id pub-id-type="pmid">26759048</pub-id></mixed-citation></ref><ref id="pone.0189485.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Nagaishi</surname><given-names>K</given-names></name>, <name><surname>Mizue</surname><given-names>Y</given-names></name>, <name><surname>Chikenji</surname><given-names>T</given-names></name>, <name><surname>Otani</surname><given-names>M</given-names></name>, <name><surname>Nakano</surname><given-names>M</given-names></name>, <name><surname>Konari</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes</article-title>. <source>Scientific reports</source>. <year>2016</year>;<volume>6</volume>:<fpage>34842</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/srep34842">10.1038/srep34842</ext-link></comment> ; PubMed Central PMCID: PMC5056395.<pub-id pub-id-type="pmid">27721418</pub-id></mixed-citation></ref><ref id="pone.0189485.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Peres</surname><given-names>GB</given-names></name>, <name><surname>Juliano</surname><given-names>MA</given-names></name>, <name><surname>Simoes</surname><given-names>MJ</given-names></name>, <name><surname>Michelacci</surname><given-names>YM</given-names></name>. <article-title>Lysosomal enzymes are decreased in the kidney of diabetic rats</article-title>. <source>Biochimica et biophysica acta</source>. <year>2013</year>;<volume>1832</volume>(<issue>1</issue>):<fpage>85</fpage>&#x02013;<lpage>95</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbadis.2012.09.011">10.1016/j.bbadis.2012.09.011</ext-link></comment> .<pub-id pub-id-type="pmid">23032151</pub-id></mixed-citation></ref><ref id="pone.0189485.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Tabata</surname><given-names>I</given-names></name>, <name><surname>Schluter</surname><given-names>J</given-names></name>, <name><surname>Gulve</surname><given-names>EA</given-names></name>, <name><surname>Holloszy</surname><given-names>JO</given-names></name>. <article-title>Lithium increases susceptibility of muscle glucose transport to stimulation by various agents</article-title>. <source>Diabetes</source>. <year>1994</year>;<volume>43</volume>(<issue>7</issue>):<fpage>903</fpage>&#x02013;<lpage>7</lpage>. .<pub-id pub-id-type="pmid">8013755</pub-id></mixed-citation></ref><ref id="pone.0189485.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Rossetti</surname><given-names>L</given-names></name>. <article-title>Normalization of insulin sensitivity with lithium in diabetic rats</article-title>. <source>Diabetes</source>. <year>1989</year>;<volume>38</volume>(<issue>5</issue>):<fpage>648</fpage>&#x02013;<lpage>52</lpage>. .<pub-id pub-id-type="pmid">2653936</pub-id></mixed-citation></ref><ref id="pone.0189485.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Bolli</surname><given-names>GB</given-names></name>, <name><surname>Di Marchi</surname><given-names>RD</given-names></name>, <name><surname>Park</surname><given-names>GD</given-names></name>, <name><surname>Pramming</surname><given-names>S</given-names></name>, <name><surname>Koivisto</surname><given-names>VA</given-names></name>. <article-title>Insulin analogues and their potential in the management of diabetes mellitus</article-title>. <source>Diabetologia</source>. <year>1999</year>;<volume>42</volume>(<issue>10</issue>):<fpage>1151</fpage>&#x02013;<lpage>67</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s001250051286">10.1007/s001250051286</ext-link></comment> .<pub-id pub-id-type="pmid">10525654</pub-id></mixed-citation></ref><ref id="pone.0189485.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Eisner</surname><given-names>C</given-names></name>, <name><surname>Faulhaber-Walter</surname><given-names>R</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Leelahavanichkul</surname><given-names>A</given-names></name>, <name><surname>Yuen</surname><given-names>PS</given-names></name>, <name><surname>Mizel</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Major contribution of tubular secretion to creatinine clearance in mice</article-title>. <source>Kidney Int</source>. <year>2010</year>;<volume>77</volume>(<issue>6</issue>):<fpage>519</fpage>&#x02013;<lpage>26</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ki.2009.501">10.1038/ki.2009.501</ext-link></comment> .<pub-id pub-id-type="pmid">20032962</pub-id></mixed-citation></ref><ref id="pone.0189485.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Bivona</surname><given-names>BJ</given-names></name>, <name><surname>Park</surname><given-names>S</given-names></name>, <name><surname>Harrison-Bernard</surname><given-names>LM</given-names></name>. <article-title>Glomerular filtration rate determinations in conscious type II diabetic mice</article-title>. <source>American journal of physiology Renal physiology</source>. <year>2011</year>;<volume>300</volume>(<issue>3</issue>):<fpage>F618</fpage>&#x02013;<lpage>25</lpage>. Epub 2010/12/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/ajprenal.00421.2010">10.1152/ajprenal.00421.2010</ext-link></comment> ; PubMed Central PMCID: PMCPmc3064143.<pub-id pub-id-type="pmid">21147841</pub-id></mixed-citation></ref><ref id="pone.0189485.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Markowitz</surname><given-names>GS</given-names></name>, <name><surname>Radhakrishnan</surname><given-names>J</given-names></name>, <name><surname>Kambham</surname><given-names>N</given-names></name>, <name><surname>Valeri</surname><given-names>AM</given-names></name>, <name><surname>Hines</surname><given-names>WH</given-names></name>, <name><surname>D'Agati</surname><given-names>VD</given-names></name>. <article-title>Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy</article-title>. <source>J Am Soc Nephrol</source>. <year>2000</year>;<volume>11</volume>(<issue>8</issue>):<fpage>1439</fpage>&#x02013;<lpage>48</lpage>. .<pub-id pub-id-type="pmid">10906157</pub-id></mixed-citation></ref><ref id="pone.0189485.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Walker</surname><given-names>RG</given-names></name>, <name><surname>Escott</surname><given-names>M</given-names></name>, <name><surname>Birchall</surname><given-names>I</given-names></name>, <name><surname>Dowling</surname><given-names>JP</given-names></name>, <name><surname>Kincaid-Smith</surname><given-names>P</given-names></name>. <article-title>Chronic progressive renal lesions induced by lithium</article-title>. <source>Kidney international</source>. <year>1986</year>;<volume>29</volume>(<issue>4</issue>):<fpage>875</fpage>&#x02013;<lpage>81</lpage>. .<pub-id pub-id-type="pmid">3012187</pub-id></mixed-citation></ref><ref id="pone.0189485.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Howard</surname><given-names>C</given-names></name>, <name><surname>Tao</surname><given-names>S</given-names></name>, <name><surname>Yang</surname><given-names>HC</given-names></name>, <name><surname>Fogo</surname><given-names>AB</given-names></name>, <name><surname>Woodgett</surname><given-names>JR</given-names></name>, <name><surname>Harris</surname><given-names>RC</given-names></name>, <etal>et al</etal>
<article-title>Specific deletion of glycogen synthase kinase-3beta in the renal proximal tubule protects against acute nephrotoxic injury in mice</article-title>. <source>Kidney international</source>. <year>2012</year>;<volume>82</volume>(<issue>9</issue>):<fpage>1000</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ki.2012.239">10.1038/ki.2012.239</ext-link></comment> .<pub-id pub-id-type="pmid">22785175</pub-id></mixed-citation></ref><ref id="pone.0189485.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Ge</surname><given-names>Y</given-names></name>, <name><surname>Dworkin</surname><given-names>L</given-names></name>, <name><surname>Peng</surname><given-names>A</given-names></name>, <name><surname>Gong</surname><given-names>R</given-names></name>. <article-title>The beta isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy</article-title>. <source>The Journal of pathology</source>. <year>2016</year>;<volume>239</volume>(<issue>1</issue>):<fpage>23</fpage>&#x02013;<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/path.4692">10.1002/path.4692</ext-link></comment> ; PubMed Central PMCID: PMC4833638.<pub-id pub-id-type="pmid">26876299</pub-id></mixed-citation></ref><ref id="pone.0189485.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Jung</surname><given-names>HJ</given-names></name>, <name><surname>Kim</surname><given-names>SY</given-names></name>, <name><surname>Choi</surname><given-names>HJ</given-names></name>, <name><surname>Park</surname><given-names>EJ</given-names></name>, <name><surname>Lim</surname><given-names>JS</given-names></name>, <name><surname>Frokiaer</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Tankyrase-mediated beta-catenin activity regulates vasopressin-induced AQP2 expression in kidney collecting duct mpkCCDc14 cells</article-title>. <source>Am J Physiol Renal Physiol</source>. <year>2015</year>;<volume>308</volume>(<issue>5</issue>):<fpage>F473</fpage>&#x02013;<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/ajprenal.00052.2014">10.1152/ajprenal.00052.2014</ext-link></comment> .<pub-id pub-id-type="pmid">25520007</pub-id></mixed-citation></ref></ref-list></back></article>